\-\ Texto\\:\\ \ \(0\)\
\-\ during\\ his\\ evaluation\\,\\ radiologic\\ studies\\ had\\ disclosed\\ a\\ contrast\\ enhancing\\ lesion\\ in\\ the\\ fourth\\ ventricle\\.\\ he\\ had\\ no\\ symptoms\\ directly\\ referable\\ to\\ the\\ fourth\\ ventricular\\ lesion\\.\\ craniotomy\\ and\\ removal\\ of\\ the\\ fourth\\ ventricular\\ tumor\\ was\\ eventually\\ performed\\.\ \(0\)\
\-\ contrast\\ enhancing\\ mass\\ in\\ the\\ inferior\\ portion\\ of\\ the\\ fourth\\ ventricle\ \(0\)\
\-\ subependymoma\\ of\\ the\\ fourth\\ ventricle\ \(0\)\
\-\ choroid\\ plexus\\ papilloma\ \(11\)\
\-\ choroid\\ plexus\\ metastasis\ \(0\)\
\-\ subependymoma\ \(6\)\
\-\ this\\ 66\\ year\\-old\\ man\\ developed\\ optic\\ neuritis\\ and\\ visual\\ loss\\ in\\ his\\ right\\ eye\\ that\\ resolved\\ with\\ steroid\\ treatment\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ fourth\\:\\ 0\\.5336804869031887\ \(0\)\
\-\ subependymoma\\:\\ 0\\.29139889254998497\ \(0\)\
\-\ ventricle\\:\\ 0\\.26284891869545157\ \(0\)\
\-\ choroid\\:\\ 0\\.223261603774311\ \(0\)\
\-\ plexus\\:\\ 0\\.21462617675758588\ \(0\)\
\-\ ventricular\\:\\ 0\\.20025119511279477\ \(0\)\
\-\ referable\\:\\ 0\\.1614280343027559\ \(0\)\
\-\ disclosed\\:\\ 0\\.15897031322767965\ \(0\)\
\-\ enhancing\\:\\ 0\\.14913060268506684\ \(0\)\
\-\ his\\:\\ 0\\.14437786258551627\ \(0\)\
\-\ the\\:\\ 0\\.14250499672438743\ \(0\)\
\-\ neuritis\\:\\ 0\\.13250090699111539\ \(0\)\
\-\ craniotomy\\:\\ 0\\.1273294308120556\ \(0\)\
\-\ eventually\\:\\ 0\\.11869982791568601\ \(0\)\
\-\ had\\:\\ 0\\.11861041848080373\ \(0\)\
\-\ directly\\:\\ 0\\.1183659566080192\ \(0\)\
\-\ contrast\\:\\ 0\\.11566866278277077\ \(0\)\
\-\ steroid\\:\\ 0\\.11472780963966653\ \(0\)\
\-\ lesion\\:\\ 0\\.11413142690052587\ \(0\)\
\-\ 66\\:\\ 0\\.1116308018871555\ \(0\)\
\-\ radiologic\\:\\ 0\\.1109233947672186\ \(0\)\
\-\ papilloma\\:\\ 0\\.10914644837507548\ \(0\)\
\-\ resolved\\:\\ 0\\.10692666045448075\ \(0\)\
\-\ optic\\:\\ 0\\.10246275240177036\ \(0\)\
\-\ visual\\:\\ 0\\.10155536981079913\ \(0\)\
\-\ eye\\:\\ 0\\.09522210106847413\ \(0\)\
\-\ removal\\:\\ 0\\.09098520415400017\ \(0\)\
\-\ in\\:\\ 0\\.08883253302411087\ \(0\)\
\-\ developed\\:\\ 0\\.08831063499873439\ \(0\)\
\-\ studies\\:\\ 0\\.08731497952896924\ \(0\)\
\-\ metastasis\\:\\ 0\\.08724032287845461\ \(0\)\
\-\ portion\\:\\ 0\\.08511647311104518\ \(0\)\
\-\ inferior\\:\\ 0\\.08097818693093045\ \(0\)\
\-\ during\\:\\ 0\\.07539344620053562\ \(0\)\
\-\ evaluation\\:\\ 0\\.07259127789859764\ \(0\)\
\-\ loss\\:\\ 0\\.07251754456548219\ \(0\)\
\-\ he\\:\\ 0\\.0704853060516534\ \(0\)\
\-\ performed\\:\\ 0\\.07041863982382877\ \(0\)\
\-\ of\\:\\ 0\\.06988103476054858\ \(0\)\
\-\ symptoms\\:\\ 0\\.06512656868806195\ \(0\)\
\-\ man\\:\\ 0\\.06301605215532971\ \(0\)\
\-\ tumor\\:\\ 0\\.0622596872180895\ \(0\)\
\-\ treatment\\:\\ 0\\.05670038795151989\ \(0\)\
\-\ that\\:\\ 0\\.051654631819670116\ \(0\)\
\-\ and\\:\\ 0\\.0491922564668028\ \(0\)\
\-\ mass\\:\\ 0\\.04546634903649082\ \(0\)\
\-\ was\\:\\ 0\\.04148319418975007\ \(0\)\
\-\ this\\:\\ 0\\.040900911439699164\ \(0\)\
\-\ right\\:\\ 0\\.039463427746118815\ \(0\)\
\-\ no\\:\\ 0\\.038707258263234304\ \(0\)\
\-\ to\\:\\ 0\\.02975730975837149\ \(0\)\
\-\ with\\:\\ 0\\.023307596220722093\ \(0\)\
